ABBV vs PLX

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Protalix (PLX) continues to exhibit strong potential for 10x growth, building on its recent financial turnaround. The stellar Q1 2026 performance, with $18.3 million net income and $0.22 GAAP EPS (as noted in prior analysis and consistent with current P/E), substantially de-risks profitability concerns. The reaffirmed 2026 revenue guidance of $78–$83 million, backed by the $25 million Chiesi miles...